Celularity Inc (CELU)
Healthcare
Biotechnology
0.64 $
-6.6%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Celularity Inc (CELU)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 65.2% of the shares are freely tradable; institutional investors hold 12.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
12.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
37.2%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
65.2%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
5.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
29Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| C V Starr & Co Inc | 2.64 | 764,069 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 2.34 | 676,650 | +0.0 | 12/31/2025 |
| Vanguard Capital Management, LLC | 2.15 | 621,105 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 0.66 | 191,076 | +19.3 | 03/31/2026 |
| BlackRock Inc | 0.44 | 127,501 | +11.0 | 03/31/2026 |
| Vanguard Fiduciary Trust Co | 0.28 | 79,874 | +0.0 | 03/31/2026 |
| State Street Corp | 0.20 | 57,830 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 1.57 | 455,049 | +0.0 | 04/30/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.57 | 166,056 | +0.0 | 04/30/2026 |
| Fidelity Extended Market Index | 0.36 | 104,816 | -0.4 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.